Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI (LP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00780858|
Recruitment Status : Completed
First Posted : October 28, 2008
Last Update Posted : May 6, 2015
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Actual Enrollment :||662 participants|
|Observational Model:||Case Control|
|Official Title:||GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI|
|Study Start Date :||October 2008|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||March 2011|
Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
Other Name: Orgalutran
Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
- Pregnancy rate [ Time Frame: 2 weeks after intervention ]
- premature luteinization [ Time Frame: at the time of intervention ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00780858
|Madrid, Spain, 28023|
|Principal Investigator:||Juan antonio García-Velasco, MD||IVI Madrid|